Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Next Previous
X
Search
Trial Profile

The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Mitomycin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MAX

    • Most Recent Events

    • 12 Sep 2018 Results published in the Annals of Oncology
    • 20 Jan 2018 Results (n=145) assessing the prognostic impact of single nucleotide polymorphisms variants (COL4A2, PPP1R17 and ARHGAPP44) and predictive effect on bevacizumab in patients from this trial, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 03 Jun 2014 Results of the predictive/prognostic impact of SNP genotype presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top